Short Interest in Apyx Medical Co. (NASDAQ:APYX) Declines By 14.6%

Apyx Medical Co. (NASDAQ:APYX) saw a significant decrease in short interest in the month of November. As of November 30th, there was short interest totalling 120,000 shares, a decrease of 14.6% from the November 15th total of 140,500 shares. Currently, 0.4% of the company’s stock are short sold. Based on an average daily trading volume, of 51,300 shares, the short-interest ratio is currently 2.3 days.

Institutional Trading of Apyx Medical

Several institutional investors and hedge funds have recently bought and sold shares of APYX. Private Advisor Group LLC raised its holdings in shares of Apyx Medical by 3.9% during the third quarter. Private Advisor Group LLC now owns 322,321 shares of the company’s stock worth $400,000 after purchasing an additional 12,180 shares during the last quarter. Commonwealth Equity Services LLC boosted its stake in shares of Apyx Medical by 2.9% in the second quarter. Commonwealth Equity Services LLC now owns 511,561 shares of the company’s stock worth $685,000 after buying an additional 14,481 shares during the last quarter. RPg Family Wealth Advisory LLC acquired a new stake in Apyx Medical during the second quarter worth about $101,000. Royce & Associates LP grew its stake in shares of Apyx Medical by 3.4% during the 3rd quarter. Royce & Associates LP now owns 2,582,490 shares of the company’s stock worth $3,202,000 after purchasing an additional 85,267 shares during the period. Finally, Rathbones Group PLC boosted its holdings in Apyx Medical by 148.0% during the second quarter. Rathbones Group PLC now owns 251,334 shares of the company’s stock worth $337,000 after buying an additional 150,000 shares in the last quarter. 55.33% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on APYX. Craig Hallum upgraded Apyx Medical to a “strong-buy” rating in a report on Thursday, October 24th. BTIG Research initiated coverage on shares of Apyx Medical in a research report on Thursday, October 17th. They issued a “neutral” rating on the stock. Finally, JMP Securities restated a “market perform” rating on shares of Apyx Medical in a research note on Monday, September 16th.

Apyx Medical Stock Performance

NASDAQ:APYX traded down $0.01 during trading hours on Friday, hitting $1.68. 33,846 shares of the company were exchanged, compared to its average volume of 80,729. The company has a debt-to-equity ratio of 3.03, a current ratio of 5.46 and a quick ratio of 4.52. Apyx Medical has a 52-week low of $0.97 and a 52-week high of $2.80. The stock has a market capitalization of $63.24 million, a price-to-earnings ratio of -2.02 and a beta of 1.27. The company’s 50 day moving average price is $1.37 and its 200-day moving average price is $1.34.

Apyx Medical (NASDAQ:APYX) last released its earnings results on Friday, November 8th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.01. The firm had revenue of $11.49 million for the quarter, compared to the consensus estimate of $11.66 million. Apyx Medical had a negative return on equity of 137.98% and a negative net margin of 58.59%. During the same period in the prior year, the firm earned ($0.13) EPS. As a group, research analysts forecast that Apyx Medical will post -0.68 earnings per share for the current year.

Apyx Medical Company Profile

Apyx Medical Corporation, an energy technology company, engages in the design, development, and manufacture of medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures.